These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33026762)

  • 21. Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumab.
    Shah CH; Princic N; Evans KA; Schultz BG
    J Med Econ; 2023; 26(1):871-877. PubMed ID: 37395381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lanadelumab to treat hereditary angioedema.
    Wedi B
    Drugs Today (Barc); 2019 Jul; 55(7):439-448. PubMed ID: 31347612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study.
    Maurer M; Lumry WR; Li HH; Aygören-Pürsün E; Busse PJ; Jacobs J; Nurse C; Ahmed MA; Watt M; Yu M;
    J Allergy Clin Immunol Pract; 2024 Jan; 12(1):201-211.e6. PubMed ID: 37730089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
    Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
    N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab.
    Wong JCY; Chiang V; Lam DLY; Lee E; Lam K; Au EYL; Li PH
    J Allergy Clin Immunol Glob; 2023 Nov; 2(4):100166. PubMed ID: 38024849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Experiencia inicial de Lanadelumab en una paciente mexicana con angioedema hereditario tipo I].
    García-Rosas C; López-Tiro JJ; Contreras-Contreras A; Ruiz-Peñaloza M; Ortiz-Monteón ZE
    Rev Alerg Mex; 2023 Sep; 70(4):194. PubMed ID: 37933935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic monoclonal antibodies with a focus on hereditary angioedema.
    Zuraw BL; Maurer M; Sexton DJ; Cicardi M
    Allergol Int; 2023 Jan; 72(1):54-62. PubMed ID: 35787344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum.
    Kőhalmi KV; Veszeli N; Cervenak L; Varga L; Farkas H
    Immunol Lett; 2017 Sep; 189():90-93. PubMed ID: 28577900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
    Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
    J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis.
    Anderson J; Soteres D; Tachdjian R; Mellor J; Earl L; Connolly H; Wynne-Cattanach K; Moran K; Sing K; Schultz BG; Juethner S
    Allergy Asthma Proc; 2024 Nov; 45(6):426-433. PubMed ID: 39293940
    [No Abstract]   [Full Text] [Related]  

  • 31. Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada.
    Iaboni A; Kanani A; Lacuesta G; Song C; Kan M; Betschel SD
    Allergy Asthma Clin Immunol; 2021 Jul; 17(1):78. PubMed ID: 34301329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term prophylaxis in hereditary angioedema management: Current practices in France and unmet needs.
    Bouillet L; Fain O; Armengol G; Aubineau M; Blanchard-Delaunay C; Dalmas MC; De Moreuil C; Du Thanh A; Gobert D; Guez S; Hoarau C; Jaussaud R; Jeandel PY; Maillard H; Marmion N; Masseau A; Menetrey C; Ollivier Y; Pelletier F; Plu-Bureau G; Sailler L; Vincent D; Bouquillon B; Verdier E; Clerson P; Boccon-Gibod I; Launay D
    Allergy Asthma Proc; 2022 Sep; 43(5):406-412. PubMed ID: 35868842
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
    Banerji A; Riedl MA; Bernstein JA; Cicardi M; Longhurst HJ; Zuraw BL; Busse PJ; Anderson J; Magerl M; Martinez-Saguer I; Davis-Lorton M; Zanichelli A; Li HH; Craig T; Jacobs J; Johnston DT; Shapiro R; Yang WH; Lumry WR; Manning ME; Schwartz LB; Shennak M; Soteres D; Zaragoza-Urdaz RH; Gierer S; Smith AM; Tachdjian R; Wedner HJ; Hebert J; Rehman SM; Staubach P; Schranz J; Baptista J; Nothaft W; Maurer M;
    JAMA; 2018 Nov; 320(20):2108-2121. PubMed ID: 30480729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lanadelumab for the treatment of hereditary angioedema.
    Wu MA
    Expert Opin Biol Ther; 2019 Dec; 19(12):1233-1245. PubMed ID: 31657963
    [No Abstract]   [Full Text] [Related]  

  • 35. Health-related quality of life among children with hereditary angioedema.
    Engel-Yeger B; Farkas H; Kivity S; Veszeli N; Kőhalmi KV; Kessel A
    Pediatr Allergy Immunol; 2017 Jun; 28(4):370-376. PubMed ID: 28258590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients.
    Federici C; Perego F; Borsoi L; Crosta V; Zanichelli A; Gidaro A; Tarricone R; Cicardi M
    BMJ Open; 2018 Jul; 8(7):e022291. PubMed ID: 30061443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial Experience of Long-Term Prophylaxis with Lanadelumab for Hereditary Angioedema in China: A Clinical Observation Study on Six Patients.
    Yao W; Diao R; Yang B; Wang Y; Li B; Li T; Ge L; Yu Y; Zhu R; Wang H
    Int Arch Allergy Immunol; 2024 Oct; ():1-11. PubMed ID: 39362190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema.
    Itzler R; Lumry WR; Sears J; Braverman J; Li Y; Brennan CJ; Koch GG
    Orphanet J Rare Dis; 2024 Jun; 19(1):241. PubMed ID: 38909246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.
    Watt M; Malmenäs M; Romanus D; Haeussler K
    J Comp Eff Res; 2023 Jun; 12(6):e220188. PubMed ID: 37218553
    [No Abstract]   [Full Text] [Related]  

  • 40. Lanadelumab (Takhzyro) for prevention of hereditary angioedema.
    Med Lett Drugs Ther; 2021 Mar; 63(1619):e41-e42. PubMed ID: 33755657
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.